MPTP Disrupts Dopamine Receptors and Dopamine Transporters

Parkinson's Disease

Volumn , Issue , 2004, Pages 433-441

  Ebadi, Manuchair ^a   Chagkutip, Jaturaporn ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85160166608     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-47     Document Type: Chapter

References (48)

1. DiChiara, G., Dopamine in the CNS I and II, Springer-Verlag, Berlin, 2002.
2. Bjöklund, A. and Lindvall, O., Catecholaminergic brain stem regulatory systems, In, Handbook of Physiology, Vol. IV, Sect. 1. (Bloom, F. E., Ed.), American Physiological Society, Bethesda, MD, 155–236, 1986.
3. Kebabian, J. W. and Calne, D. B., Multiple receptors for dopamine, Nature, 277:93–96, 1979.
4. Seeman, P., Dopamine receptors and the dopamine hypothesis of schizophrenia, Synapse, 1:133–152, 1987.
5. Dearry, A., Gingrich, J. A., Falardeau, P., Fremeau, R. T. Jr., Bates, M. D. and Caron, M. G., Molecular cloning and expression of the gene for a human D1 dopamine receptor, Nature, 347:72–76, 1990.
6. Monsma, F. J., Jr., McVittie, L. D., Gerfen, C. R., Mahan, L. C. and Sibley, D. R., Multiple D2 dopamine receptors produced by alternative splicing, Nature, 342:926–929, 1989.
7. Sunahara, R. K., Guan, H. C., O’Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. M. and Niznik, H. B., Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1, Nature. 350:614–619, 1991.
8. Zhou, Q. Y., Grandy, D. K., Thambi, L., Kushner, J. A., Van Tol, H. H. M., Cone, R., Pribnow, D., Salon, J., Bunzow, J. R. and Civelli, O., Cloning and expression of human and rat D1 dopamine receptors, Nature, 347:76–80, 1990.
9. Bunzow, J. R., Van Tol, H. H. M., Grandy, D. K, Albert, P., Salon, J., Christie, M., Machida, C. A., Neve, K. A. and Civelli, O., Cloning and expression of a rat D2 dopamine receptor cDNA, Nature, 336:783–787, 1988.
10. Dal Toso, R., Sommer, B., Ewert, M., Herb, A., Pritchett, D. B., Bach, A., Shivers, B. D. and Seeburg, P. H., The dopamine D2 receptor: Two molecular forms generated by alternative spicing, EMBO J., 8:4025–4034, 1989.
11. Giros, B., Sokoloff, P., Martres, M. P., Riou, J. F., Emorine, L. J. and Schwartz, J. C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms, Nature, 342:923–926, 1989.
12. Frothigham, L, Fischer, J. B., Burke-Howie, K. J., Bunzow, J. R., Server, A. C. and Civelli, O., Cloning of the cDNA and gene for a human D2 dopamine receptor, Proc. Natl. Acad. Sci. USA, 86:9762–9766, 1989.
13. Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L. and Schwartz, J. C., Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics, Nature, 347:146–151, 1990.
14. Van Tol, H. H. M., Bunzow, J. R., Guan, H. C., Sunahara, R K., Seeman, P., Niznik, H. B. and Civelli, O., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Nature, 350:610–614, 1991.
15. Vallar, L and Meldolesi, J. Mechanisms of signal transduction at the dopamine D2 receptor, Trends Pharmacol. Sci., 10:74–77, 1989.
16. Ebadi, M., Pfeiffer, R. F. and Murrin, L. C., Pathogenesis and treatment of neuroleptic malignant syndrome, Gen. Pharmacol., 21:367–386, 1990.
17. Ebadi, M., Pfeiffer, R. F. and Murrin, L. C., Neurolepticinduced movement disorders, in Current Aspects of the Neurosciences, Vol. 4., Ed., Osborne, N. N., Macmillan Press, pp. 159–203, 1992.
18. O’Dowd, B. F., Structures of dopamine receptors, J. of Neurochem., 60:804–816, 1993.
19. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M. and Caron M. G., Dopamine receptors: From structure to function, Pharmacological Reviews, 78:189–225, 1998.
20. Strange, P. G. Dopamine Receptors, TOCR’s Reviews, 15:1–5, 2000.
21. Glickstein, S. B. and Schmauss, C., Dopamine receptor functions: Lessons from knockout mice, Pharmacology and Therapeutics, 91:63–83, 2001.
22. Giros, B., Jaber, M., Jones, S., Wightman, R. M. and Caron, M. G., Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter, Nature, 379, 606–616, 1996.
23. Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M. and Caron, M. G., Profound neuronal plasticity in response to inactivation of the dopamine transporter, Proc. Natl. Acad. Sci. USA., 95:4029–4034, 1998.
24. Jones, S. R., Gainetdinov, R. R., Wightman, R. M. and Caron, M. G., Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter, J. Neurosci., 18:1979–1986, 1998.
25. Giros, B. and Caron, M. G., Molecular characterization of the dopamine transporter, Trends in Pharmacol. Sci., 14:43–49, 1993.
26. Chen, N. and Reith, M. E. A., Structure and function of the dopamine transporter, Eur. J. Pharmacol., 405: 329–339, 2000.
27. Reith, M. E. A., Xu, C. and Chen, N. H., Pharmacology and regulation of the neuronal dopamine transporter, Eur. J. Pharmacol., 324:1–10, 1997.
28. Chen, N. H. and Reith, M. E. A. Structure and function of the dopamine transporter, Eur. J. Pharamacol., 405: 329–339, 2000.
29. Reith, M. E. A., Neurotransmitter transporters structure, function, and regulation, 2nd ed., Human Press, New Jersey, 2002.
30. Tipton, K. F. and Singer, T. P., Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds, J. Neurochem., 61:1191–1206, 1993.
31. Gainetdinov, R. R., Fumagalli, F., Jones, S. R. and Caron, M. F., Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter, J. Neurochem,. 69:1322–1325, 1997.
32. Javitch, J. A., D’Amato, R. J., Strittmatter, S. M. and Snyder, S., Parkinsonism-inducing neurotoxin, Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenyl pyridium by dopamine neurons explains selective toxicity, Proc. Natl. Acad. Sci. USA, 82: 2173–2177, 1982.
33. Amara, S. G. and Kuhar, M. J., Neurotransmitter transporters: Recent progress, Ann. Rev. Neurosci., 16: 73–93, 1993.
34. Reith, M. E., Xu, C. and Chen, N. H., Pharmacology and regulation of the neuronal dopamine transporter, Eur. J. Pharmacol., 324:1–10, 1997.
35. Uhl, G. R., Walther, D., Mash, D., Faucheux, B. and Javoy-Agid, F., Dopamine transporter messenger RNA in Parkinson’s disease and control substantia nigra neurons, Ann. Neurol., 35: 494–498, 1994.
36. Harrington, K. A., Augood, S. J., Kingsbury, A. E., Foster, O. J. and Emson, P. C., Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson’s disease, Brain Res. Mol. Brain Res., 36: 157–162, 1996.
37. Speciale, S. G., Liang, C. L., Sonsalla, P. K., Edwards, R. H. and German, D. C., The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter, Neuroscience. 84: 177–1185, 1998.
38. Chang, G. D. and Ramirez, V D., The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro, Brain Res., 368: 134–140, 1986.
39. Obata, T. and Chiueh, C. C., In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: Effects of MPTP, MPDP+, and MPP+, J. Neural Transm. Gen. Sect., 89:139–145, 1992.
40. Lotharius, J. and O’Malley, K. L., The parkinsonisminducing drug 1-methyl-4 phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity, J. Biol. Chem., 275: 38581–38588, 2000.
41. Przedborski, S. and Jackson-Lewis, V., Mechanisms of MPTP toxicity, Mov. Disord., 13: 35–38, 1998.
42. Ramsay, R. R., Salach, J. I. and Singer, T. P., Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+, Biochem. Biophys. Res. Commun., 134: 743–748, 1986.
43. Barc, S., Page, G., Fauconneau, B., Barrier, L. and Huguet, F., A new in vitro approach for investigating the MPTP effect on DA uptake, Neurochem. Int., 38:243–248, 2001.
44. Fonck, C. and Baudry, M., Toxic effects of MPP+ and MPTP in PC12 cells independent of reactive oxygen species formation, Brain Res., 905: 199–206, 2001.
45. Fonck, C. and Baudry, M., Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria, Brain Res., 975: 214–221, 2003.
46. Storch, A., Ludolph, A. C. and Schwarz, J., HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism, Neurochem. Int., 35: 393–403, 1999.
47. Chagkutip, J., Vaughan, R. A., Govitrapong, P. and Ebadi, M., 1-Methyl-4-phenylpyridinium-induced down-regulation of dopamine transporter function correlates with a reduction in dopamine transporter cell surface expression, Biomedical and Biophysical Research Comm., Vol. 311, 49:49–54, 2003.
48. Richerson, G B. and Wu, Y. M., Dynamic equilibrium of neurotransmitter transporters: Not just for reuptake anymore, J. Neurophysiology, Vol. 90, 1363–1374, 2003.